192 related articles for article (PubMed ID: 25458308)
1. Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging.
Mielke MM; Weigand SD; Wiste HJ; Vemuri P; Machulda MM; Knopman DS; Lowe V; Roberts RO; Kantarci K; Rocca WA; Jack CR; Petersen RC
Alzheimers Dement; 2014 Nov; 10(6):779-89. PubMed ID: 25458308
[TBL] [Abstract][Full Text] [Related]
2. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.
Racine AM; Clark LR; Berman SE; Koscik RL; Mueller KD; Norton D; Nicholas CR; Blennow K; Zetterberg H; Jedynak B; Bilgel M; Carlsson CM; Christian BT; Asthana S; Johnson SC
J Alzheimers Dis; 2016 Oct; 54(4):1395-1408. PubMed ID: 27589532
[TBL] [Abstract][Full Text] [Related]
3. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
4. Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries.
Buckley RF; Sparks KP; Papp KV; Dekhtyar M; Martin C; Burnham S; Sperling RA; Rentz DM
J Prev Alzheimers Dis; 2017; 4(1):3-11. PubMed ID: 29188853
[TBL] [Abstract][Full Text] [Related]
5. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
[TBL] [Abstract][Full Text] [Related]
6. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
8. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
9. Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI.
Lim YY; Pietrzak RH; Bourgeat P; Ames D; Ellis KA; Rembach A; Harrington K; Salvado O; Martins RN; Snyder PJ; Masters CL; Rowe CC; Villemagne VL; Maruff P
Arch Clin Neuropsychol; 2015 Feb; 30(1):49-58. PubMed ID: 25467942
[TBL] [Abstract][Full Text] [Related]
10. Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging.
Wennberg AM; Gustafson D; Hagen CE; Roberts RO; Knopman D; Jack C; Petersen RC; Mielke MM
J Alzheimers Dis; 2016 May; 53(2):573-81. PubMed ID: 27163809
[TBL] [Abstract][Full Text] [Related]
11. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Rocca WA; Knopman DS; Mielke MM; Lowe VJ; Senjem ML; Gunter JL; Preboske GM; Pankratz VS; Vemuri P; Petersen RC
Lancet Neurol; 2014 Oct; 13(10):997-1005. PubMed ID: 25201514
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance.
Pudumjee SB; Lundt ES; Albertson SM; Machulda MM; Kremers WK; Jack CR; Knopman DS; Petersen RC; Mielke MM; Stricker NH
J Alzheimers Dis; 2021; 83(2):861-877. PubMed ID: 34366338
[TBL] [Abstract][Full Text] [Related]
13. Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals.
Lim YY; Williamson R; Laws SM; Villemagne VL; Bourgeat P; Fowler C; Rainey-Smith S; Salvado O; Martins RN; Rowe CC; Masters CL; Maruff P;
J Alzheimers Dis; 2017; 58(4):1293-1302. PubMed ID: 28550258
[TBL] [Abstract][Full Text] [Related]
14. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
[TBL] [Abstract][Full Text] [Related]
15. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment.
Stricker NH; Lundt ES; Albertson SM; Machulda MM; Pudumjee SB; Kremers WK; Jack CR; Knopman DS; Petersen RC; Mielke MM
J Alzheimers Dis; 2020; 76(1):261-274. PubMed ID: 32538841
[TBL] [Abstract][Full Text] [Related]
17. Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort.
Mielke MM; Machulda MM; Hagen CE; Christianson TJ; Roberts RO; Knopman DS; Vemuri P; Lowe VJ; Kremers WK; Jack CR; Petersen RC
Alzheimers Dement; 2016 Mar; 12(3):281-91. PubMed ID: 26602629
[TBL] [Abstract][Full Text] [Related]
18. Multimorbidity Is Associated with Preclinical Alzheimer's Disease Neuroimaging Biomarkers.
Mendes A; Tezenas du Montcel S; Levy M; Bertrand A; Habert MO; Bertin H; Dubois B; Epelbaum S;
Dement Geriatr Cogn Disord; 2018; 45(5-6):272-281. PubMed ID: 29953971
[TBL] [Abstract][Full Text] [Related]
19. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.
Wirth M; Oh H; Mormino EC; Markley C; Landau SM; Jagust WJ
Alzheimers Dement; 2013 Nov; 9(6):687-698.e1. PubMed ID: 23474040
[TBL] [Abstract][Full Text] [Related]
20. Reliability and validity of the CogState computerized battery in patients with seizure disorders and healthy young adults: comparison with standard neuropsychological tests.
Fratti S; Bowden SC; Cook MJ
Clin Neuropsychol; 2017 Apr; 31(3):569-586. PubMed ID: 27852143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
